{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Kaposi%27s+Sarcoma&page=2",
    "query": {
      "condition": "Recurrent Kaposi's Sarcoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Kaposi%27s+Sarcoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T08:09:58.870Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00096538",
      "title": "Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "valganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 6,
      "start_date": "2004-04",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2015-11-25",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 3,
      "location_summary": "New York, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096538"
    },
    {
      "nct_id": "NCT00002936",
      "title": "Altretamine and Etoposide in Treating Patients With HIV-Related Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "altretamine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1996-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-04",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002936"
    },
    {
      "nct_id": "NCT03038672",
      "title": "Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALK-Positive Large B-Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
        "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation",
        "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
        "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "EBV-Positive Mucocutaneous Ulcer",
        "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Intravascular Large B-Cell Lymphoma",
        "Large B-Cell Lymphoma With 11q Aberration",
        "Large B-Cell Lymphoma With IRF4 Rearrangement",
        "Plasmablastic Lymphoma",
        "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
        "Primary Effusion Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Burkitt Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Gray-Zone Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent Lymphomatoid Granulomatosis",
        "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Recurrent Primary Mediastinal Large B-Cell Lymphoma",
        "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Burkitt Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Gray-Zone Lymphoma",
        "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Refractory Primary Mediastinal Large B-Cell Lymphoma",
        "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varlilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2018-12-21",
      "completion_date": "2026-10-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038672"
    },
    {
      "nct_id": "NCT01016730",
      "title": "Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AIDS-Related Kaposi Sarcoma",
        "HIV Infection",
        "Recurrent Kaposi Sarcoma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2010-01-22",
      "completion_date": "2015-01-07",
      "has_results": false,
      "last_update_posted_date": "2018-02-20",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 9,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01016730"
    },
    {
      "nct_id": "NCT00474994",
      "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Malignant Fibrous Histiocytoma of Bone",
        "Desmoid Tumor",
        "Endometrial Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 53,
      "start_date": "2007-04",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474994"
    },
    {
      "nct_id": "NCT00003008",
      "title": "Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "indinavir sulfate",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        },
        {
          "name": "saquinavir mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 33,
      "start_date": "1997-12-15",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003008"
    },
    {
      "nct_id": "NCT01154452",
      "title": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Alveolar Soft Part Sarcoma",
        "Adult Angiosarcoma",
        "Adult Desmoplastic Small Round Cell Tumor",
        "Adult Epithelioid Hemangioendothelioma",
        "Adult Epithelioid Sarcoma",
        "Adult Extraskeletal Myxoid Chondrosarcoma",
        "Adult Extraskeletal Osteosarcoma",
        "Adult Fibrosarcoma",
        "Adult Leiomyosarcoma",
        "Adult Liposarcoma",
        "Adult Malignant Mesenchymoma",
        "Adult Malignant Peripheral Nerve Sheath Tumor",
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Adult Unclassified Pleomorphic Sarcoma",
        "Chondrosarcoma",
        "Clear Cell Sarcoma of the Kidney",
        "Conjunctival Kaposi Sarcoma",
        "Dermatofibrosarcoma Protuberans",
        "Gastrointestinal Stromal Tumor",
        "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Metastatic Osteosarcoma",
        "Ovarian Sarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Kaposi Sarcoma",
        "Recurrent Osteosarcoma",
        "Recurrent Uterine Corpus Sarcoma",
        "Small Intestine Leiomyosarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage III Uterine Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Stage IV Uterine Sarcoma",
        "Unclassified Pleomorphic Sarcoma of Bone"
      ],
      "interventions": [
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2010-06",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154452"
    },
    {
      "nct_id": "NCT00020449",
      "title": "Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "recombinant interleukin-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-01",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020449"
    },
    {
      "nct_id": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Differentiated Thyroid Gland Carcinoma",
        "Advanced Head and Neck Carcinoma",
        "Advanced Hepatocellular Carcinoma",
        "Advanced Kaposi Sarcoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Advanced Lung Small Cell Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Melanoma",
        "Advanced Ovarian Carcinoma",
        "Advanced Prostate Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Advanced Thyroid Gland Medullary Carcinoma",
        "Advanced Triple-Negative Breast Carcinoma",
        "Advanced Urothelial Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Castration-Resistant Prostate Carcinoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "HIV Infection",
        "Metastatic Differentiated Thyroid Gland Carcinoma",
        "Metastatic Head and Neck Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Kaposi Sarcoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Thyroid Gland Medullary Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Differentiated Thyroid Gland Carcinoma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Kaposi Sarcoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Lung Small Cell Carcinoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Thyroid Gland Medullary Carcinoma",
        "Recurrent Triple-Negative Breast Carcinoma",
        "Recurrent Urothelial Carcinoma",
        "Refractory Differentiated Thyroid Gland Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2021-11-22",
      "completion_date": "2027-02-06",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04514484"
    },
    {
      "nct_id": "NCT00090987",
      "title": "Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AIDS Malignancy Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-06",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-06-10T08:09:58.870Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • Los Angeles, California • Palm Springs, California + 11 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090987"
    }
  ]
}